Detalhe da pesquisa
1.
Correlation of immune fitness with response to teclistamab in relapsed/refractory multiple myeloma in MajesTEC-1.
Blood;
2024 Apr 24.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38657201
2.
Teclistamab in Relapsed or Refractory Multiple Myeloma.
N Engl J Med;
387(6): 495-505, 2022 08 11.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35661166
3.
Plain language summary of the MajesTEC-1 study of teclistamab for the treatment of people with relapsed or refractory multiple myeloma.
Future Oncol;
19(12): 811-818, 2023 Apr.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37132225
4.
Teclistamab, a B-cell maturation antigenâ×âCD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study.
Lancet;
398(10301): 665-674, 2021 08 21.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34388396
5.
Teclistamab impairs humoral immunity in patients with heavily pretreated myeloma: importance of immunoglobulin supplementation.
Blood Adv;
8(1): 194-206, 2024 01 09.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38052042
6.
Population Pharmacokinetics and Exposure-Response with Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma: Results From MajesTEC-1.
Target Oncol;
18(5): 667-684, 2023 09.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37713090
7.
Translational Modeling Predicts Efficacious Therapeutic Dosing Range of Teclistamab for Multiple Myeloma.
Target Oncol;
17(4): 433-439, 2022 07.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35749004
8.
Effects of teclistamab and talquetamab on soluble BCMA levels in patients with relapsed/refractory multiple myeloma.
Blood Adv;
7(4): 644-648, 2023 02 28.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36006441
9.
Correction: Translational Modeling Predicts Efficacious Therapeutic Dosing Range of Teclistamab for Multiple Myeloma.
Target Oncol;
17(5): 609, 2022 Sep.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35913648